NLRP1/NALP1 Antibody [Unconjugated]

Western blot shows lysates of HEK293 human embryonic kidney cell line either mock transfected, transfected with human NLRP1/NALP1 or transfected with NALP3, THP-1 human acute monocytic leukemia cell line, and Ramos human Burkitt's lymphoma cell line. PVDF Membrane was probed with 0.5 µg/mL of Sheep Anti-Human NLRP1/NALP1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6788) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). Specific bands were detected for NLRP1/NALP1 at approximately 160 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 2.

DPP8/9 inhibitors activate the CARD8 inflammasome in T cells. A–c Human primary CD3+ T cells were pre-treated with the indicated compounds for 30 min prior to the addition of VbP (2 μM, 6 h). Cell viability was assessed using Cell-TiterGlo. Data are means ± s.e.m. of four or five biological replicates. ***p < 0.001 by two-sided Student’s t test. NS not significant. d Immunoblots of CARD8 KO CD3+ T-cell lysates treated with VbP (20 μM, 24 h). e, f CD3+ T cells (Donor 008) were primed with LPS (10 μg/mL, 4 h) before treatment with the indicated concentrations of VbP (6 h), LT (6 h), Lfn-flagellin (3 h), or nigericin (1 h). Lysates were then evaluated by immunoblotting (e) and supernatants were analyzed for LDH release (f) and IL-1 beta secretion (g). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32796818), licensed under a CC-BY license. Not internally tested by R&D Systems.

DPP8/9 inhibitors induce pyroptosis in primary lymphocytes.a Domain structures of human NLRP1 and CARD8. Note that the ZU5 and UPA sub-domains together are referred to as a FIIND. b, c The indicated primary cells were treated with VbP (24 h) before cell death was assessed by Cell-TiterGlo (b) and lysates were evaluated by immunoblotting (c). Data are means ± s.e.m. of four biological replicates. d CD3+ T cells were treated with VbP (20 μM, 24 h) or 8j (20 μM, 24 h) before lysates were evaluated by immunoblotting. Immunoblots are representative of three independent experiments. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32796818), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: WB
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Unconjugated
• Concentration: LYOPH

NLRP1/NALP1 Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human NLRP1/NALP1
  Met1-Asp323 (Leu155His)
  Accession # Q9C000
• Specificity: Detects human NLRP1/NALP1 in direct ELISAs and Western blots. In direct ELISAs, less than 2% cross-reactivity with recombinant human (rh) NALP2 and rhNALP3 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Gene: NLRP1
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.5 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Sterile PBS to a final concentration of 0.2 mg/mL.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for NLRP1/NALP1 Antibody [Unconjugated]

• CARD7
• CARD7SLEV1
• Caspase recruitment domain-containing protein 7
• CLR17.1
• Death effector filament-forming ced-4-like apoptosis protein
• DEFCAP
• DEFCAPVAMAS1
• DKFZp586O1822
• KIAA0926DEFCAP-L/S
• NACHT, leucine rich repeat and PYD (pyrin domain) containing 1
• NACHT, leucine rich repeat and PYD containing 1
• NACHT, LRR and PYD containing protein 1
• NACHT, LRR and PYD domains-containing protein 1
• NACPP1044
• NALP1
• NALP1caspase recruitment domain protein 7
• NLR family, pyrin domain containing 1
• NLRP1
• Nucleotide-binding domain and caspase recruitment domain
• nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domaincontaining 1
• PP1044
• SLEV1
• VAMAS1

Background

NALP1 (NAcht, Leucine-rich repeat and PYD domain containing protein 1; also NAC, CARD7, DEFCAP and CLR17.1) is a 160-170 kDa member of the NLRP family of molecules. It is expressed in dendritic cells, neutrophils, T and B cells, alveolar macrophages, permatogonia, neurons, plus intestinal columnar epithelium, and is found in both cytoplasm and nucleus. NALP1 promotes apoptosis plus IL-1 beta and IL-18 maturation by activating caspase-1 and -5. It does so by forming a 700 kDa inflammasome comprised of NALP1, ASC plus caspase-1 and -5. Bacterial wall peptidoglycan binds to NALP1, promoting ATP binding, NALP1 oligomerization, and caspase activation. Human NALP1 is 1473 amino acids (aa) in length. It contains an N-terminal DAPIN domain (aa 1-92), a NACHT domain (aa 328-637), seven consecutive LRRs (aa 704-1236) and one CARD region (aa 1374-1463). Alternate splice forms exist that range in size from 70 kDa-150 kDa. Either individually, or in combination, there can be a 19 aa substitution for either aa 1353-1473 or aa 1368-1472, a deletion of aa 91-260, 958-987 or 1262-1305, and a 43 aa insert after Leu785. Over aa 1-323, human NALP1 shares less that 20% aa identity with mouse NALP1.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for NLRP1/NALP1 Antibody (AF6788)(12)

Publications using AF6788

• Rodríguez-Ruiz, L;Lozano-Gil, JM;Naranjo-Sánchez, E;Martínez-Balsalobre, E;Martínez-López, A;Lachaud, C;Blanquer, M;Phung, TK;García-Moreno, D;Cayuela, ML;Tyrkalska, SD;Pérez-Oliva, AB;Mulero, V; ZAK?/P38 kinase signaling pathway regulates hematopoiesis by activating the NLRP1 inflammasome EMBO molecular medicine 2023-09-07 [PMID: 37675820] (Immunoprecipitation, Human)
• Pinilla M, Mazars R, Verg� R et al. EEF2-inactivating toxins engage the NLRP1 inflammasome and promote epithelial barrier disruption Journal of Experimental Medicine 10/2/2023 [PMID: 37642996]
• Pinilla M, Mazars R, Verg� R et al. EEF2-inactivating toxins engage the NLRP1 inflammasome and promote epithelial barrier disruption Journal of Experimental Medicine 2023-10-02 [PMID: 37642996]
• EL Orth-He, HC Huang, SD Rao, Q Wang, Q Chen, CM O'Mara, AJ Chui, M Saoi, AR Griswold, A Bhattachar, DP Ball, JR Cross, DA Bachovchin Protein folding stress potentiates NLRP1 and CARD8 inflammasome activation Cell Reports, 2023-01-16;0(0):111965. 2023-01-16 [PMID: 36649711] (Western Blot, Human)
• Planes R, Pinilla M, Santoni K et al. Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells Molecular cell 5/16/2022 [PMID: 35594856]
• SD Rao, Q Chen, Q Wang, EL Orth-He, M Saoi, AR Griswold, A Bhattachar, DP Ball, HC Huang, AJ Chui, DJ Covelli, S You, JR Cross, DA Bachovchin M24B aminopeptidase inhibitors selectively activate the CARD8 inflammasome Nature Chemical Biology, 2022-02-14;0(0):. 2022-02-14 [PMID: 35165443] (Western Blot, Human)
• DC Johnson, MC Okondo, EL Orth, SD Rao, HC Huang, DP Ball, DA Bachovchin DPP8/9 inhibitors activate the CARD8 inflammasome in resting lymphocytes Cell Death Dis, 2020-08-14;11(8):628. 2020-08-14 [PMID: 32796818] (Western Blot, Human)
• Ball DP, Taabazuing CY, Griswold AR et al. Caspase-1 interdomain linker cleavage is required for pyroptosis Life Sci Alliance 3/1/2020 [PMID: 32051255]
• M Krze?niak, A Zajkowicz, A Gdowicz-K?, M G?owala-Ko, B ?asut-Szys, M Rusin Synergistic activation of p53 by actinomycin D and nutlin-3a is associated with the upregulation of crucial regulators and effectors of innate immunity Cell. Signal., 2020-02-04;69(0):109552. 2020-02-04 [PMID: 32032660] (Western Blot, Human)
• SB Drutman, F Haerynck, FL Zhong, D Hum, NJ Hernandez, S Belkaya, F Rapaport, SJ de Jong, D Creytens, SJ Tavernier, K Bonte, S De Scheppe, J van der We, L Lorenzo-Di, A Wullaert, X Bossuyt, G Orth, VR Bonagura, V Béziat, L Abel, E Jouanguy, B Reversade, J Laurent-Ca Homozygous NLRP1 gain-of-function mutation in siblings with a syndromic form of recurrent respiratory papillomatosis Proc. Natl. Acad. Sci. U.S.A., 2019-09-04;0(0):. 2019-09-04 [PMID: 31484767] (Western Blot, Human)
• DC Johnson, CY Taabazuing, MC Okondo, AJ Chui, SD Rao, FC Brown, C Reed, E Peguero, E de Stanchi, A Kentsis, DA Bachovchin DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia Nat. Med., 2018-07-02;0(0):. 2018-07-02 [PMID: 29967349] (Western Blot, Human)
• D'Osualdo A, Anania V, Yu K, Lill J, Kaufman R, Matsuzawa S, Reed J Transcription Factor ATF4 Induces NLRP1 Inflammasome Expression during Endoplasmic Reticulum Stress. PLoS ONE, 2015-06-18;10(6):e0130635. 2015-06-18 [PMID: 26086088] (Immunoprecipitation, Human)

Bioinformatics

• Gene Symbol: NLRP1
• Uniprot:
  • Q9C000(Human)